Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma

NCT04807972 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04807972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04807972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
May 28, 2021
Completion date
March 25, 2024
Enrollment
40 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer